Vascular endothelial growth factor gene therapy - Helixmith
Alternative Names: VMDA-3601Latest Information Update: 08 Aug 2019
At a glance
- Originator Dong-A Pharmaceutical; ViroMed Co Ltd
- Class Cytokine genes; Gene therapies; Growth factors
- Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Peripheral arterial occlusive disorders
Most Recent Events
- 13 Oct 2010 Discontinued - Phase-II for Peripheral arterial occlusive disorders in South Korea (IM)
- 01 Aug 2007 VMDA 3601 is still in active development
- 26 Jan 2004 Phase-II clinical trials in Peripheral arterial occlusive disorders in South Korea (IM)